- Deltex Medical Group, the global leader in oesophageal Doppler monitoring, has added two further new accounts to its platform programme in the US.

The first new account is a major teaching hospital in the mid-west region of the US and is the second platform programme account in the Great Lakes sales territory which the company established in the first quarter of 2015.

The hospital has indicated that it intends to purchase at least 40 probes per month during its initial implementation phase, which the Company expects to increase as the technology is more widely adopted. Approximately 20 probes per month are scheduled to be used in the hospital's breast reconstruction surgical protocols to be launched in January 2016. The second new account is a large hospital in Washington State. It is the fourth platform programme account in the North-West sales territory, and the fourth platform programme account from the 26 strong hospital system with which the company implemented a system-wide procurement framework agreement in January 2015. The agreement requires each hospital that participates to commit to purchase at least 30 adult surgical probes a month. The three existing accounts are all on track to get to 100 or more probes per month: they are each now regularly purchasing 50 to 65 probes per month having started their implementation programmes at 30 to 35 probes a month. This fourth new account's first order was for 50 probes. The new account contains a full service children's hospital with a large regional catchment area. Following a successful evaluation of the company's newly launched paediatric probes, the company has entered discussions with the hospital system to expand the purchasing agreement to include paediatric probes.

At 9:02am: [LON:DEMG] Deltex Medical Group PLC share price was +0.25p at 4.25p

Story provided by